Non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib. However, secondary somatic EGFR mutations (e.g., T790M) confer resistance to erlotinib. BMS-690514, a novel panHER/vascular endothelial growth factor receptor (VEGFR) inhibitor described here, exerted antiproliferative and proapoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation. In this model, BMS-690514 induced a G 1 cell cycle arrest, as well as ultrastructural hallmarks of apoptosis, mitochondrial release of cytochrome c, and activation of caspases involved in the intrinsic (e.g., caspase-2, caspase-3, caspase-7, and caspase-9), but not in the extrinsic (e.g., caspase-8), pathway. Caspase inhibition conferred partial protection against BMS-690514 cytotoxicity, pointing to the involvement of both caspasedependent and caspase-independent effector mechanisms. Transcriptome analyses revealed the up-regulation of proapoptotic (e.g., Bim, Puma) and cell cycle inhibitory (e.g., p27
Introduction
Most patients with non-small cell lung cancer (NSCLC, the most frequent cancer in males) present at an inoperable stage, with a poor prognosis (1) . Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is aberrantly activated in several epithelial solid tumors, and notably in NSCLC (2) . Overexpression of the gene coding for EGFR has been found in 40% to 80% of NSCLC biopsies, and has been correlated with shorter survival after surgical resection (3) . Activating mutations of EGFR may render NSCLC cells independent from external growth factors (4), converting EGFR into an attractive therapeutic target (5) . For the treatment of NSCLC, small-molecule EGFR tyrosine kinase inhibitors (EGFR-TKI), like erlotinib (Tarceva) and gefitinib (Iressa), have been evaluated (6) . However, only erlotinib prolonged the survival of patients with recurrent NSCLC (7) . In particular, a subset of patients carrying EGFR-activating mutations exhibited encouraging responses to EGFR-TKIs (8) . The deletion DE746-A750 in exon 19 and the leucine-to-arginine substitution at position 858 (L858R) in exon 21 account for 85% of NSCLC-related EGFR mutations (9) . Deletions in exon 19 are associated with better responses to EGFR-TKIs and prolonged overall survival, compared with activating mutations in exon 21 (i.e., L858R; ref. 10) . Nevertheless, secondary mutations, including the threonine-tomethionine substitution at position 790 (T790M, in exon 20) and the aspartate-to-tyrosine substitution at position 761 (D761Y, in exon 19) , have been reported in lesions progressing after treatment with EGFR-TKIs (11) . At present, it is not clear whether the T790M mutation is present in a small fraction of tumor cells before treatment (12) or whether it arises de novo (13) . Recently, it has been shown that alternative EGFR-TKI inhibitors retain the ability to promote apoptosis in gefitinib-resistant cancer cells (14) .
EGFR signaling is linked to multiple intracellular pathways that inhibit apoptosis and promote survival and proliferation. Upon ligand-induced activation, EGFR generates phosphotyrosine sites for the recruitment of Ras and phosphatidylinositol-3 kinase, setting off the classic mitogen-activated protein kinase and Akt pathways (15) . Moreover, several members of the signal transducer and activator of transcription (STAT) family of transcriptional factors (e.g., STAT1, STAT3, STAT5a, and STAT5b) can be activated by EGFR (16) . Interestingly, the inhibition of STAT3 promotes apoptosis in cells expressing mutant EGFR (17) .
Apoptosis is an accurately regulated program by which vertebrates eliminate superfluous, ectopic, and damaged cells (18, 19) , as well as one of the mechanisms through which chemotherapeutics kill cancer cells (20) . The cell death program is at least partially suppressed during oncogenesis, thus favoring chemotherapy and radiotherapy resistance (21, 22) . Apoptosis can be distinguished from other cell death subroutines by means of morphologic criteria, including chromatin condensation (pyknosis) and nuclear fragmentation (karyorhexis; refs. 23, 24) . Cells that succumb to apoptosis eventually break down into membrane-enclosed bodies, which, in vivo, are engulfed by resident phagocytic cells and usually fail to elicit inflammatory/immune responses (23, 25) .
Apoptosis may be executed via the extrinsic pathway, which emanates from the extracellular environment and is propagated along the ''death receptors ! death-inducing signaling complex ! caspase-8'' axis (26) (27) (28) , or through an intracellular cascade of events that involves mitochondria (intrinsic pathway; refs. 29, 30) . In this case, proapoptotic signals from several subcellular compartments (e.g., the nucleus, the endoplasmic reticulum, etc.) are transmitted to mitochondria where they promote mitochondrial membrane permeabilization, often through the activation of proapoptotic proteins of the Bcl-2 family (22, 31) . After mitochondrial membrane permeabilization, cytotoxic proteins that normally reside in the intermembrane space are liberated into the cytosol, and can either favor directly the activation of the caspases, as does cytochrome c (32), or promote apoptosis in a caspase-independent fashion (33), as do apoptosis-inducing factor (34) (35) (36) and endonuclease G (37) .
In the present article, we report the characterization of a novel panHER/vascular endothelial growth factor receptor (VEGFR) inhibitor, BMS-690514, that exerts antiproliferative and proapoptotic effects on NSCLC cell lines, in particular on cells that are resistant to erlotinib due to the T790M mutation. In addition, we describe the mechanisms through which BMS-690514 exerts is cytostatic and cytotoxic effects.
Materials and Methods
Cell lines, culture, and treatments. A549 cells [wild-type (wt) EGFR and p53] were grown in F12-K medium containing L-glutamine, supplemented with 10% FCS, 100 units/mL penicillin G sodium, and 100 Ag/mL streptomycin sulfate. H1299 cells (wt EGFR, inactive p53 R175H), H1650 cells (bearing a deletion in exon 19 of the EGFR gene, i.e., DE746-A750, and wt p53), and H1975 cells (EGFR L858R/T790M and wt p53) were maintained in RPMI 1640 with GlutaMAX supplemented with 10% FCS and antibiotics (as above). For proliferation and cytotoxicity assays based on 96-well plates, all cell lines were cultured in DMEM/F12 (1:1) with L-glutamine but no phenol red supplemented with 10% FCS and antibiotics. Media and supplements were purchased from Life Technologies-Invitrogen.
For fluorescence-activated cell sorting (FACS) analysis, 20 Â 10 3 to 25 Â 10 3 cells were seeded in 12-well plates 12 h before the treatment with BMS-690514 (Bristol Myers Squibb), in the presence or absence of the pancaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD-fmk, 25 Amol/L, from Bachem) or of the nuclear factor-nB (NF-nB) inhibitor Bay 11-7082 (10 Amol/L, from Sigma-Aldrich).
For transcriptome analysis, 1 Â 10 5 to 2 Â 10 5 cells were seeded in sixwell plates, allowed to adhere for 12 h, and then left untreated or treated
for an additional 48 h (24 h). Thereafter, cells were harvested, lysed for the extraction of RNA, and processed to analyze gene expression, as previously reported (38) .
For proliferation assays, 1 Â 10 3 to 3 Â 10 3 cells were seeded in 96-well plates 12 h before the treatment with BMS-690514 or erlotinib (Tarceva, from Sequoia). When the sequential administration of BMS-690514 and CDDP was investigated, cells were treated with 5 Amol/L BMS-690514 for 24 h (48 h) before the administration of 10 Amol/L CDDP for additional 48 h (24 h) or vice versa. In both cases, treatments lasted a total of 72 h, after which plates were analyzed for cell proliferation.
For transmission electron microscopy, H1975 cells were treated for 48 h with 5 Amol/L BMS-690514, then fixed and processed as previously reported (39) .
Cell proliferation assays. Cell proliferation was quantified by means of a colorimetric assay based on the reduction of the colorless tetrazolium salt 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1, from Roche) to formazan (which exhibit an absorbance peak around 450 nm), according to the manufacturer's instructions.
Small interfering RNA transfections. Detailed information on the small interfering RNAs (siRNA) can be found in Supplementary Materials and Methods. For 96-well plates based proliferation assays, A549 and H1975 cells were transfected while seeded, as follows. siRNA (300 pmol) dissolved in 2.1 mL of serum-free, antibiotic-free, DMEM:F12 (1:1) with L-glutamine but no phenol red were mixed with 63 AL of HiPerFect transfection reagent (Qiagen) dissolved in 2.1 mL of the same medium and allowed to stand at room temperature for 30 min. Thereafter, transfection complexes were added to f2.35 Â 10 5 cells suspended in 7.8 mL of DMEM/F12 (1:1) with L-glutamine but no phenol red supplemented with 10% FCS and antibiotics. The resulting cell suspension was seeded into a 96-well plate (f3,500 cells in 100 AL of medium per well). Transfected cells were cultured for 48 h before the administration of BMS-690514 (25 and 70 Amol/L for H1975 and A549 cells, respectively) or CDDP (70 Amol/L for both cell lines). Finally (after a total of 72 h), plates were analyzed for cell proliferation.
For FACS analysis, H1975 cells were reverse transfected after a slightly modified protocol. One hundred picomoles of siRNA (unrelated, caspase-2, p65) dissolved in 92 AL of serum-free, antibiotic-free RPMI 1640 with GlutaMAX were mixed with 8 AL of HiPerFect transfection reagent, and allowed to stand at room temperature for 30 min. Then, transfection complexes were added to 10 5 cells suspended in 1.9 mL of RPMI 1640 with GlutaMAX supplemented with 10% FCS and antibiotics, and the resulting suspension was seeded into six-well plates. After 48 h (to allow for protein down-regulation), cells were harvested and transferred to 12-well plates (30 Â 10 3 to 40 Â 10 3 per well). Upon adhesion to the plate, cells were retransfected with the siRNAs originally used (to grant for persistent downregulation) by means of the HiPerFect transfection reagent (Qiagen), in this case following the manufacturer's instructions. Simultaneously, cells were treated or not with 5 Amol/L BMS-690514. After an additional 48 h, cells were subjected to cytofluorimetric analysis of viability and Dw m dissipation.
Data treatment and statistical analysis. All experiments were done in duplicates or triplicates, and repeated at least twice. Data are reported as means F SE. Statistical significance was evaluated by means of paired Student's t test. The assay-independent indicator D was introduced to allow for normalization among different assays, and to analyze the effects of siRNAs per se separately from their influence on drug-induced cell death. A precise mathematical definition of D may be found in Supplementary Materials and Methods.
Cytofluorometric analysis and immunofluorescence. Cells were stained with the following probes to assess apoptosis-associated modifications: propidium iodide (1 Ag/mL, Sigma-Aldrich) for viability and dihexyloxacarbocyanine iodide [DiOC 6 (3), 40 nmol/L, Molecular ProbesInvitrogen] for Dw m dissipation (40) . Caspase-3 activation was measured by staining with an FITC-conjugated monoclonal antibody specific for active caspase-3 (Becton Dickinson). After overnight fixation of the cells in glacial 70% ethanol, DNA content was quantified by staining with propidium
Cancer Research
Cancer Res 2007; 67: (13 iodide (50 Ag/mL) and RNase (10 Ag/mL, Roche) for 30 min at room temperature. All cytofluorimetric analyses were done using a FACScan equipped with Cell Quest software (Becton Dickinson).
For immunofluorescence studies, cells were fixed with paraformaldehyde (4% w/v in PBS) followed by staining with antibodies for the detection of cytochrome c (mouse monoclonal IgG anti-cytochrome c; BD PharMingen) and active caspase-3 [rabbit polyclonal anti caspase-3 (Asp 175 ); Cell Signaling Technology]. Nuclei were counterstained with 10 Ag/mL Hoechst 33342 (Molecular Probes-Invitrogen). Primary antibodies were revealed either with goat anti-rabbit IgG conjugated to Alexa 488 (green) or with goat anti-mouse IgG conjugated to Alexa 568 (red) from Molecular ProbesInvitrogen. Fluorescence microscopy determinations were done by means of a Leica IRE2 microscope equipped with a Leica DC300F camera.
Analysis of protein expression. Protein samples of H1975 cells were prepared in lysis buffer, according to standard established protocols (41) . Extracted proteins (50 Ag/lane) were separated by 12% SDS-PAGE and subjected to immunoblots using mouse monoclonal IgG1 antibodies specific for caspase-2 (Santa Cruz Biotechnology), active caspase-8, phosphorylated EGFR (Cell Signalling Technology), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon International) and rabbit polyclonal antibodies against caspase-3, caspase-7, active caspase-9 (Cell Signalling Technology), total EGFR, or the p65 subunit of NF-nB (Santa Cruz Biotechnology). Membranes were then incubated with secondary goat antimouse or anti-rabbit IgG conjugated to horseradish peroxidase (Southern Biotech) before revelation with ECL Detection kit and Hyperfilm X-ray films (both from Amersham Pharmacia).
Results and Discussion
BMS-690514 kills erlotinib-resistant NSCLC cells by apoptosis. BMS-690514 is a novel specific inhibitor of EGFR, exhibiting an in vitro IC 50 of f5 nmol/L. 11 At higher concentrations, it acts also on other members of the EGFR family (i.e., Erb-B2 and Erb-B4, with an IC 50 of f20 and f60 nmol/L, respectively) as well as on VEGFR2 (IC 50 of f50 nmol/L).
11 BMS-690514 inhibits the proliferation of NSCLC cell lines, showing a marked effect on the H1975 cell line that expresses an EGFR mutation (T790M) that is associated with clinical resistance against erlotinib. The antiproliferative effect of BMS-690514 on H1975 cells was obtained at an IC 50 of f1 Amol/L, which is 10-fold lower than the IC 50 of erlotinib (Fig. 1A) . It was associated with a marked increase in cells manifesting signs of apoptosis including the dissipation of the mitochondrial transmembrane potential [Dw m , as assessed by staining with the potential-sensitive probe DiOC 6 (3)] and the permeabilization of the plasma membrane (as measured by staining with the vital dye propidium iodide). H1975 cells (EGFR L858R/T790M, wt p53) were by far more sensitive to BMS-690514 than H1650 (EGFR DE746-A750, wt p53), H1299 (wt EGFR, inactive p53), and A549 (wt EGFR, wt p53) NSCLC cell lines (Fig. 1B) . Transmission electron microscopy revealed that H1975 cells transit from a normal morphology (Supplementary Fig. S1A ) to full-blown apoptosis when treated with BMS-690514. After an initial swelling of the Golgi apparatus ( Supplementary Fig. S1B ) and the accumulation of pseudomyelinic figures in the cytoplasm (Supplementary Fig. S1C and S1D) , the three defining hallmarks of apoptosis, namely nuclear condensation (pyknosis, Supplementary  Fig. S1E ) and fragmentation (karyorhexis, Supplementary Fig. S1F ), and apoptotic blebbing ( Supplementary Fig. S1G ) became manifest. Then, the dying cells either were phagocytosed by yet alive neighbors ( Supplementary Fig. S1H ) or underwent secondary necrosis ( Supplementary Fig. S1I ). In conclusion, BMS-690514 induces the apoptotic demise of H1975 NSCLC cells.
Cellular effects of BMS-690514: cell cycle inhibition and induction of the mitochondrial caspase activation pathway. To characterize the mechanisms through which BMS-690514 kills H1975 cells, we determined its transcriptional effects at a preapoptotic stage, measured at 24 h (at a dose of BMS-690514, 5 Amol/L, which kills 50% of the cells after 48 h of incubation) or at 48 h (at a dose of BMS-690514, 1 Amol/L, which kills 50% of the cells after 72 h of incubation). All data obtained by microarray analysis have been submitted to Array Express at the European Bioinformatics Institute 12 with the accession number E-TABM-239 (42) . At 24 h, BMS-690514 caused the up-regulation of f250 genes and the down-regulation of f500 genes by a factor >2, with a profile that was markedly different from that induced by CDDP ( Fig. 2A ; see also Supplementary Table S1 ). Hence, part of the changes in the transcriptome are specific for BMS-690514 and do not reflect a general property of apoptosis in H1975 cells. Of note, BMS-690514 suppressed the expression of several cell cycleassociated proteins (cyclins B1, D1, and D3; CDK1; members of the minichromosome maintenance family, i.e., MCM-3, MCM-4, MCM-6, MCM-7, and MCM-10; PCNA), whereas it induced two CDK1 inhibitors CDKN1B (p27 kip1 ) and CDKN1C (p57 kip2 ; Fig. 2B ). In the same conditions, BMS-690514 led to a G 1 cycle arrest (Fig. 3A) that preceded the overt induction of apoptosis recorded after 72 h (Fig. 1B) . This has important consequences on the antitumor response mediated by the DNA-damaging agent CDDP. Because CDDP preferentially kills proliferating cells, it loses its cytotoxic activity when added to short-term BMS-690514-pretreated (and hence G 1 arrested) cells. In contrast, BMS-690514 mediates cytotoxic/antiproliferative effects even after pretreatment with CDDP, as shown in experiments in which CDDP and BMS-690514 were added in different orders to H1975 cells (Fig. 3B) .
BMS-690514 influenced several genes that are involved in the mitochondrial cell death pathway. It induced several transcripts whose products can induce mitochondrial membrane permeabilization, namely the proapoptotic BH3-only proteins from the Bcl-2 family Bim (by a factor of 3) and Bbc3/Puma (by a factor of 2.5) as well as p53AP1 (by a factor of 2). In addition, BMS-690514 down-regulated several cytoprotective proteins: the antiapoptotic Bcl-2 homologue Mcl-1 and several members of the HSP family (HSP40, HSP70, HSP90; Fig. 2B ). In this context, it may be noteworthy that HSP90 promotes the stability of mutant EGFR and that the use of HSP90 inhibitors (like the geldanamycin derivative 17-AAG) may represent a novel approach for the therapy of NSCLC (43) .
BMS-690514 induced signs of the mitochondrial apoptosis pathway. Thus, H1975 cells treated with BMS-690514 manifested the release of cytochrome c and subsequent caspase-3 activation, as determined by two-color immunofluorescence staining, immunoblotting, and cytofluorimetric quantification (Fig. 4A-C) . BMS-690514-activated caspases that contribute to the mitochondrial pathway (including caspase-2, caspase-3, caspase-7, and caspase-9; Fig. 4B ), yet failed to induce the proteolytic maturation of caspase-8, which characterizes the extrinsic pathway of apoptosis (Fig. 4B) . Z-VAD-fmk ( Fig. 4B and C) retarded cell death induced by BMS-690514 (Fig. 1B) . On the contrary, Z-VAD-fmk failed to prevent the dephosphorylation of EGFR promoted by BMS-690514; it also did not (or very slightly) affected the BMS-690514-mediated downregulation of EGFR (Fig. 4D ). This correlated with the transcriptional effects of BMS-690514 on various chaperons of the HSP family, some of which have been implicated in the internalization and degradation of EGFR (43) .
siRNA screening of cell death modulators reveals the importance of Bcl-2 family proteins and NF-KB for BMS-690514-induced killing. To further explore the mechanisms accounting for BMS-690514 cytotoxicity, we transfected a panel of f40 validated siRNAs into H1975 cells and determined their influence on the antiproliferative effects mediated by BMS-690514. To this aim, transfected cells were treated with BMS-690514 for 24 h, before the assessment of proliferation by a tetrazolium salt reduction assay. The effect of each siRNA was evaluated by comparing the residual proliferation, as measured upon the treatment with BMS-690514, to the level observed in untreated (transfected) cells (Fig. 5A and B) . Results were then compared with the negative control provided by an irrelevant, ''unrelated'' siRNA. In H1975 cells, several siRNAs attenuated the cytotoxic effects of BMS-690514. This applies in particular to siRNAs targeting proapoptotic members of the Bcl-2 family This table is an excerpt from Supplementary Table S1 , which contains a complete list of genes that are transcriptionally modulated by BMS-690514 by a factor higher than 2. n.s., nonstatistically significant P value (>10 Fig. 5C ). In contrast, the knock down of components of the NF-nB-activating system (p65, Nemo/IKKg, TAB2) sensitized H1975 cells to death mediated by BMS-690514 (Fig. 5C) . It is important to note that the profile of siRNAmediated modulation of BMS-690514 cytotoxicity, as obtained in H1975 cells, was rather specific and hence very different from that observed for another cell death inducer (CDDP) on the same cell line, or that observed for a cell line bearing wt EGFR (A549) treated with either BMS-690514 or CDDP (Fig. 5C and D) . Using a different readout, namely the cytofluorimetric quantification of dying [DiOC 6 (3) low ] and dead (propidium iodide positive) cells, we could confirm that the knock down of caspase-2 reduced the lethal effect of BMS-690514 on H1975 cells, whereas that of the NF-nB subunit p65 sensitized to BMS-690514 ( Fig. 6A and B) . Similarly, inhibition of the NF-nB-activating kinase IKK1 with BAY 11-7082 sensitized to cell death induction by BMS-690514 (Fig. 6C) . Altogether, these data validate the notion that BMS-690514 kills through a mitochondrial pathway that is controlled by the NF-nB system.
Concluding remarks. Clinical data indicate that EGFR-targeted therapies may provide advantages over traditional chemotherapeutic regimens for the treatment of advanced NSCLC. However, objective responses are limited to a subset of patients who invariably develop resistance against currently available EGFR-TKIs such as erlotinib and gefitinib. Novel EGFR-TKI overcoming drug resistance might represent important weapons in the fight against cancer.
As shown here, BMS-690514 was able to arrest proliferation and/or to induce apoptosis in all tested NSCLC cell lines, although at different levels of potency. Importantly, BMS-690514 exhibited a prominent effect on cells affected by the T790M mutation of EGFR, which confers resistance against erlotinib. The proapoptotic effects of BMS-690514 were only partially counteracted by the pancaspase inhibitor Z-VAD-fmk, suggesting the involvement of caspase-dependent as well as of caspase-independent mechanisms in BMS-690514-mediated killing. Accordingly, BMS-690514 was in insets ) . Thereafter, cell proliferation was assessed by an assay based on the reduction of the tetrazolium salt WST-1. The switch between the two treatments was done either at 24 h (left) and at 48 h (right ). Control cultures were administered with medium (M ) only. For each panel, the proliferation of treated cultures was normalized to that of control cells subjected to the exchange of the culture medium at the same time points. Columns, mean of triplicate experiments; bars, SE. **, sequential treatments providing antiproliferative effects that differ in a statistically significant fashion (P < 0.05) from the effects obtained with both drugs separately.
able to elicit the proteolytic maturation of several caspases involved in the mitochondrial apoptotic pathway (e.g., caspase-2, caspase-3, caspase-7, and caspase-9), as determined by immunoblotting. On the other hand, caspase-8, which is specifically linked to the activation of death receptors, was not activated. Moreover, siRNA-mediated down-regulation of caspase-2 provided partial protection against BMS-690514-induced cell death. It has been previously reported that caspase-2 is necessary for the death of PC12 cells and sympathetic neurons induced by withdrawal of obligate trophic factors (44) (45) (46) . Interestingly, our results point Total cell lysates were then separated on SDS-PAGE and analyzed by immunoblotting with antibodies against total caspase-2, caspase-3, and caspase-7 as well as against active caspase-8, caspase-9, and GAPDH (loading control). The activation of caspases coincides with a reduction in the intensity of the procaspase band (P ) paralleled by an increase of the band corresponding to the active fragment(s) (A ). C, H1975 cells were incubated with BMS-690514 at the indicated concentration (in the absence or presence of 25 Amol/L Z-VAD-fmk) for 24 h, followed by the cytofluorometric quantification of caspase-3 activation. Columns, means of duplicate experiments; bars, SE. **, significant (P < 0.05) differences. D, H1975 protein extracts obtained as in (B ) were analyzed by immunoblotting with antibodies specific for total (T ) or phosphorylated (p) EGFR as well as for GAPDH (loading control). again to the involvement of caspase-2 in the lethal pathways emanating from inhibited transmembrane growth factor receptors.
BMS-690514 sensitized NSCLC cells to the antiproliferative and proapoptotic activity of CDDP, the most frequently chemotherapeutic agent used for the treatment of NSCLC. This synergistic effect was only seen when BMS-690514 was administered after CDDP, and not vice versa. The fact that CDDP lost its effects on BMS-690514-pretreated cells can be explained by the G 1 -arresting effect of BMS-690514, which reduces the fraction of cells in the S phase (the preferential target of CDDP toxicity). Altogether, these results point to the possibility of performing combination chemotherapies with improved efficacy, using an appropriate schedule of sequential drug administrations.
siRNA-mediated knock down of several proteins with an established role in apoptosis indicates that BMS-690514 activates the intrinsic, mitochondrial pathway leading to cell death. BMS-690514 did not induce any death receptors nor their ligands (and did not promote the proteolytic activation of caspase-8), yet changed the balance between antiapoptotic and proapoptotic members from the Bcl-2 family (by reducing Mcl-1 and inducing Bim, Puma, and Bad) at the transcriptional level. Accordingly, siRNA-mediated depletion of several BH3-only proteins from the Bcl-2 family (Puma, Bad) or of two of the proapoptotic multidomain members of the family (Bax or Bak, but in particular the combination of both) reduced the cytotoxic effect of BMS-690514. Finally, cells treated with BMS-690514 manifested signs of mitochondrial membrane permeabilization, including the partially caspase-dependent release of cytochrome c and Dw m dissipation. Surprisingly, our siRNA screening revealed that the downregulation of ERCC1, which in NSCLC constitutes both a positive prognostic marker and a predictive factor for the sensitivity to CDDP-based adjuvant chemotherapy (47) , reduced the lethal effects of BMS-690514. Similarly, we found that the depletion of other proteins involved in the DNA damage response or telomere maintenance (FANCC, FAND2, Chk1, and hTERT) also reduced BMS-690514 cytotoxicity, through hitherto unexplored mechanisms. This suggests that NSCLC that overexpress ERCC1 or hTERT might be particularly amenable to the treatment by BMS-690514 or similar agents. Our siRNA screening also led to identification of a series of targets whose depletion sensitized to BMS-690514. Several among these targets are involved in the antiapoptotic NF-nB pathway, and inhibition of NF-nB might indeed increase the sensitivity of tumor cells to BMS-690514.
In conclusion, BMS-690514 and its analogues might constitute an addition to the armamentarium of EGFR-TKIs used to fight NSCLC. As shown here, BMS-690514 can act on cells that are resistant to the Food and Drug Administration-approved EGFR-TKI erlotinib by exerting both cytostatic and cytotoxic activities, the latter involving the activation of the mitochondrial cell death pathway.
